EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Treprostinil and Clinical Outcome in Pulmonary Hypertension and Interstitial Lung Disease

Roberto G Carbone, Assaf Monselise, Francesco Puppo

CHEST · 2023

DOI: 10.1016/j.chest.2023.04.015 ↗

Kurz gefasst

Leserbrief in der Zeitschrift CHEST, 2023. Verfasst von Roberto G Carbone und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Genoa, Genoa, Italy. Electronic address: magister1@mail.com. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Lung Diseases, Interstitial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryLung Diseases, InterstitialHumansNaphazolineEpoprostenolAntihypertensive AgentsTreatment Outcome

Substanzen

treprostinilNaphazolineEpoprostenolAntihypertensive Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Genoa, Genoa, Italy. Electronic address: magister1@mail.com.
  • Clalit Health Services, Tel Aviv, Israel.
  • Department of Internal Medicine, University of Genoa, Genoa, Italy.

Zitieren

APA

Carbone, R. G., Monselise, A., & Puppo, F. (2023). Treprostinil and Clinical Outcome in Pulmonary Hypertension and Interstitial Lung Disease. CHEST. https://doi.org/10.1016/j.chest.2023.04.015

Vancouver

Carbone RG, Monselise A, Puppo F. Treprostinil and Clinical Outcome in Pulmonary Hypertension and Interstitial Lung Disease. CHEST. 2023. doi:10.1016/j.chest.2023.04.015

BibTeX
@article{Carbone2023,
  author = {Carbone, Roberto G and Monselise, Assaf and Puppo, Francesco},
  title = {Treprostinil and Clinical Outcome in Pulmonary Hypertension and Interstitial Lung Disease},
  journal = {CHEST},
  year = {2023},
  doi = {10.1016/j.chest.2023.04.015}
}
Kostenlos starten →